ORPHA:213767
Squamous cell carcinoma of the cervix uteri
Also known as: Cervical squamous cell carcinoma
Publications
17,441
97.6th percentile
Trials
80
Interventional, condition-specific
Researchers
1,026
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0006143
- UMLS:C0279671
- NCIT:C4028
Additional Mondo synonyms (12)
cervical squamous cell cancer · cervical squamous cell carcinoma · cervix squamous cell carcinoma · cervix uteri squamous cell carcinoma · squamous cell carcinoma of cervix · squamous cell carcinoma of cervix uteri · squamous cell carcinoma of the cervix · squamous cell carcinoma of the cervix uteri · squamous cell carcinoma of the uterine cervix · squamous cell carcinoma of uterine cervix · squamous cervical cancer · uterine cervix squamous cell carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
17,441 matched papers (12,287 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
80 matched on ClinicalTrials.gov (10 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
28
Drugs / clinical candidates · MONDO_0006143
- CARBOPLATIN·phase 3
- CEMIPLIMAB·phase 3
- CISPLATIN·phase 3
- NIMOTUZUMAB·phase 3
- PACLITAXEL·phase 3
- BEVACIZUMAB·phase 2
- CADONILIMAB·phase 2
- CAMRELIZUMAB·phase 2
- CAPECITABINE·phase 2
- DOCETAXEL·phase 2
- DOXORUBICIN HYDROCHLORIDE·phase 2
- ERLOTINIB·phase 2
- EXATECAN MESYLATE·phase 2
- GEMCITABINE·phase 2
- IPILIMUMAB·phase 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
17,441
17,441 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
17,441 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
12,287 in the last 10 years · high confidence · 97.6th percentile (publications denominator)
Phrase hits: 17,441 · MeSH hits: 0
Who's working on it?
1,026
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Chen Y8 papers · 2026
Guangzhou Institute of Cancer Research, the Affiliated Cancer Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510095, China.
Papers in Europe PMC - 02Huang Y7 papers · 2026
The Department of Gynecology, Obstetrics and Gynecology Center, The First Hospital of Jilin University, Changchun 130000, China. Electronic address: 1913543386@qq.com.
Papers in Europe PMC - 03Li D7 papers · 2026
Department of Biochemistry and Molecular Biology, School of Medicine, Shihezi University, Xinjiang Endemic and Ethnic Disease and Education Ministry Key Laboratory, Shihezi, Xinjiang, 832002, China.
Papers in Europe PMC - 04Li J7 papers · 2026
Department of Radiotherapy Oncology, The Second Affiliated Hospital of Dalian Medical University, Dalian, China.
Papers in Europe PMC - 05Wang L7 papers · 2026
Department of Gynecological Oncology, The 1st Affiliated Hospital of Bengbu Medical University, Bengbu, China.
Papers in Europe PMC - 06Zhang X7 papers · 2026
Department of Pathology, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University Chengdu, China.
Papers in Europe PMC - 07Zhang Y7 papers · 2026
Department of Gynecology, Lihuili Hospital Affiliated to Ningbo University, Ningbo, Zhejiang, China.
Papers in Europe PMC - 08Li X6 papers · 2025
Department of Gynecology, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital, Zhengzhou, Henan, People's Republic of China.
Papers in Europe PMC - 09Li Y6 papers · 2026
Zhejiang Key Laboratory of Maternal and Infant Health, Women's Hospital, Zhejiang University School of Medicine, China.
Papers in Europe PMC - 10Zhang J6 papers · 2026
Department of Pathology, Shandong Provincial Maternal and Child Health Care Hospital Affiliated to Qingdao University, Jinan, Shandong, China.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
80
interventional trials for this specific condition
80 interventional trials matched this specific condition name; 10 currently recruiting in our sample. 2,477 trials are registered for squamous cell carcinoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
80 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 98.2th percentile).
high confidence · 98.2th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
80 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07061977·RECRUITING·Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Not reviewed·Conditions: Locally Advanced Cervical Adenocarcinoma · Locally Advanced Cervical Adenosquamous Carcinoma · Locally Advanced Cervical Squamous Cell Carcinoma · Stage IIIA Cervical Cancer FIGO 2018·Matched via name phrase
- NCT07169734·RECRUITING·A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
Not reviewed·Conditions: Cervical Squamous Cell Carcinoma · Squamous Non-small-cell Lung Cancer · Colorectal Cancer · Intrahepatic Cholangiocarcinoma·Matched via name phrase
- NCT07602842·NOT YET RECRUITING·A Study of IDP-001 in Advanced or Metastatic Solid Tumors
Not reviewed·Conditions: Advanced Solid Tumor · Metastatic Solid Tumor · Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma·Matched via name phrase
- NCT05910827·RECRUITING·A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Not reviewed·Conditions: Advanced or Metastatic Squamous Non-Small Cell Lung Cancer · Advanced Head and Neck Squamous Cell Carcinoma · Advanced Esophageal Squamous Cell Carcinoma · Cervical Squamous Cell Carcinoma·Matched via name phrase
- NCT06747585·RECRUITING·A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Not reviewed·Conditions: Squamous Non-small-cell Lung Cancer · Head and Neck Squamous Cell Carcinoma · Cervical Squamous Cell Carcinoma · Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT07217171·RECRUITING·A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
Not reviewed·Conditions: Bladder Cancer · Squamous Cell Carcinoma of the Lung · Esophageal Squamous Cell Carcinoma · Tongue Squamous Cell Carcinoma·Matched via name phrase
- NCT06505551·NOT YET RECRUITING·Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma
Not reviewed·Conditions: HPV-Related Squamous Cell Carcinoma · HPV-Related Cervical Squamous Cell Carcinoma · HPV-Related Vulvar Squamous Cell Carcinoma · HPV-Related Penile Squamous Cell Carcinoma·Matched via name phrase
- NCT04712851·RECRUITING·Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia
Not reviewed·Conditions: Cervical Intraepithelial Neoplasia · Cervical Squamous Cell Carcinoma In Situ · Cervical Squamous Intraepithelial Neoplasia 2·Matched via name phrase
- NCT07435376·RECRUITING·Intra-lesional Tumor Boost for Bulky Cervical Cancer
Not reviewed·Conditions: Cervical Cancer · Squamous Cell Carcinoma of Cervix·Matched via name phrase
- NCT06543576·RECRUITING·External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer
Not reviewed·Conditions: Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma · Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8·Matched via name phrase
Broader category: squamous cell carcinoma
2,477
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06662058·RECRUITING·Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Not reviewed·Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 · Cutaneous Squamous Cell Carcinoma of the Head and Neck · Head and Neck Carcinoma of Unknown Primary · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT06540443·RECRUITING·Pilot Study of MPB-2043 Enhanced MRI for Nodal Staging in Head and Neck Squamous Cell Carcinomas
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Lymph Node Metastasis·Matched via name phrase
- NCT06599775·NOT YET RECRUITING·Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer
Not reviewed·Conditions: Resectable Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT07173270·NOT YET RECRUITING·Improved Oral Health in Head and Neck Cancer Survivors
Not reviewed·Conditions: Head and Neck Cancer Squamous Cell Carcinoma · Head and Neck Cancer·Matched via name phrase
- NCT07487896·RECRUITING·A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
Not reviewed·Conditions: Advanced Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06659146·RECRUITING·Thermotherapy in Addition to SOC Palliative Radiotherapy
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Cutaneous Squamous Cell Carcinoma · Breast Cancer Recurrent·Matched via name phrase
- NCT07726199·RECRUITING·Study Comparing Different Neck Treatment Approaches in Patients With Oral Cancer Without Visible Neck Spread
Not reviewed·Conditions: Oral Squamous Cell Carcinoma (OSCC)·Matched via name phrase
- NCT06589609·RECRUITING·Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Not reviewed·Conditions: Oropharyngeal Squamous Cell Carcinoma (SCC)·Matched via name phrase
- NCT06161532·RECRUITING·Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · Small Cell Carcinoma of the Urinary Tract · Squamous Cell Carcinoma of the Bladder · Squamous Cell Carcinoma of the Urinary Tract·Matched via name phrase
- NCT06915454·RECRUITING·High-Resolution PET-CT Imaging for Surgical Margin Visualization
Not reviewed·Conditions: Cancer · Solid Malignant Tumors · SCC - Squamous Cell Carcinoma · HNSCC·Matched via name phrase
- NCT06693323·RECRUITING·Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC
Not reviewed·Conditions: HNSCC · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07629817·NOT YET RECRUITING·Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant Immunochemotherapy
Not reviewed·Conditions: Esophageal Squamous Cell Carcinoma·Matched via name phrase
- NCT06648096·RECRUITING·Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Not reviewed·Conditions: Fanconi Anemia · Head and Neck Squamous Cell Carcinoma·Matched via name phrase
- NCT07392580·RECRUITING·Intralesional Chemotherapy (IC): Cisplatin + Epinephrine
Not reviewed·Conditions: Laryngeal Squamous Cell Carcinoma·Matched via name phrase
- NCT05747625·RECRUITING·(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma
Not reviewed·Conditions: Head and Neck Squamous Cell Carcinoma · Metastatic Head and Neck Squamous Cell Carcinoma · Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck·Matched via name phrase
Observational and natural-history studies
10 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT04976478·NOT YET RECRUITING·Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma
Not reviewed·Conditions: Cervical Squamous Cell Carcinoma·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 61 · after dedupe 61 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 61 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (61)
- ctis·2024-516870-31-00·Authorised, ongoing·A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK‑8294 Monotherapy in Advanced Solid Tumors
skipped — LLM skipped (--skip-llm)
- ctis·2022-501253-37-00·Expired·A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Advanced Solid Tumors (KEYNOTE-158)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16805365·No longer recruiting·Chart review assessing venetoclax treatment outcomes for AML - AML Real World Evidence Initiative (ARC)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10978180·Stopped·A Phase 1b/IIa trial to explore the combination of a new drug, PLX-7486, with gemcitabine in patients with advanced cancer (part 1b) and with advanced pancreatic ductal cancer and cancer-related pain (Part IIa)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN38690336·No longer recruiting·Is it safe to add cediranib to weekly paclitaxel chemotherapy in women with ovarian cancer who are at risk of developing malignant bowel obstruction?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41579286·No longer recruiting·PRIMETIME – Post-operative avoidance of radiotherapy in minimal risk women: patient selection using biomarkers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN28039294·No longer recruiting·Anti-CD47 antibody therapy in relapsed/refractory Haematological Malignancies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN30090285·No longer recruiting·Trial of PAZOpanib with or without FOSbretabulin in advanced recurrent ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83343031·No longer recruiting·A Phase II Trial to Assess the Activity of NY-ES-O1 Targeted T Cells in Advanced Oesophagogastric Cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN69481429·No longer recruiting·Dose escalation trial of oral Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) inhibitor, Vandetanib in combination with the oral Mitogen Activated Kinase (MEK) inhibitor, Selumetinib (VanSel-1) in solid tumours (dose escalation) and NSCLC (expansion cohort)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN63150635·No longer recruiting·6-mercaptopurine (6MP) and low-dose methotrexate in patients with known BRCA defective tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN65902492·No longer recruiting·A Cancer Research UK phase I trial of adoptive transfer of autologous tumour antigen specific T-cells with pre-conditioning chemotherapy and intravenous interleukin-2 (IL2) in patients with advanced carcinoembryonic antigen (CEA) positive tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59158409·No longer recruiting·Radiotherapy, Irinotecan, Capecitabine then Excision for locally advanced rectal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN32336114·No longer recruiting·A phase II trial of sequential treatment with cytoreductive therapy and reduced intensity conditioning allogeneic stem cell transplantation for relapsed/ refractory acute myeloid leukemia, high risk myelodysplasia, or other high risk myeloid malignancies
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN79708370·No longer recruiting·Value of Comprehensive Geriatric Assessment, clinical judgment, and performance status in the treatment of patients with epithelal ovarian carcinoma aged 70 years and older
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN99195212·No longer recruiting·An open, randomised, multicentre trial of Tomudex (ZD1694) versus 5-Fluorouracil (5-FU) and Leucovorin (LV) in patients with advanced colorectal carcinoma
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN78982321·No longer recruiting·A multicentre randomised study of dose-intensive chemotherapy as primary treatment in a multimodality approach for locally advanced or inflammatory breast cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN38929731·No longer recruiting·Comparison of radical radiotherapy with or without chemotherapy for poor prognosis carcinoma of cervix
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26689999·No longer recruiting·A multicentre, randomised trial of primary chemotherapy in inoperable cervical cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN68324339·No longer recruiting·2x2 factorial randomised phase III study comparing standard versus whole bladder volume radiotherapy with and without synchronous chemotherapy in muscle invasive bladder cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN27785591·No longer recruiting·A randomised trial of combination bleomycin, ifosfamide and cisplatinum versus single agent cisplatinum in recurrent cervical cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN62918594·No longer recruiting·A Phase I/IIa trial of HMBD-001 in advanced HER3-positive solid tumours
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN51679511·Recruiting·A feasibility trial to test whether having all treatment before surgery is a better way of treating oesophageal cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10073073·Recruiting·A study testing the safety and effects of FB-102 in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49366748·No longer recruiting·A phase II study to test the safety and effects of BC-006 Injection in adults with obesity
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Squamous cell carcinoma of the cervix uteri — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Squamous cell carcinoma of the cervix uteri" OR "Squamous cell carcinoma of cervix uteri" OR "Cervical squamous cell carcinoma" OR "cervical squamous cell cancer" OR "cervix squamous cell carcinoma" OR "cervix uteri squamous cell carcinoma" OR "squamous cell carcinoma of cervix" OR "squamous cell carcinoma of the cervix" OR "squamous cell carcinoma of the uterine cervix" OR "squamous cell carcinoma of uterine cervix" OR "squamous cervical cancer" OR "uterine cervix squamous cell carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Squamous cell carcinoma of the cervix uteri" OR "Squamous cell carcinoma of cervix uteri" OR "Cervical squamous cell carcinoma" OR "cervical squamous cell cancer" OR "cervix squamous cell carcinoma" OR "cervix uteri squamous cell carcinoma" OR "squamous cell carcinoma of cervix" OR "squamous cell carcinoma of the cervix" OR "squamous cell carcinoma of the uterine cervix" OR "squamous cell carcinoma of uterine cervix" OR "squamous cervical cancer" OR "uterine cervix squamous cell carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 80 interventional · 10 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"squamous cell carcinoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:38:03.099Z
